Using primary cells from patients with chronic myelomonocytic leukemia, Vanderbilt researchers found synergistic inhibition of cell viability and proliferation, suggesting a new treatment strategy.

Laura Kennedy, MD, PhD, has joined Vanderbilt University Medical Center from the University of Washington School of Medicine/Fred Hutchinson Cancer Research Center in Seattle where she was acting instructor and research associate.

Immune checkpoint inhibitors have transformed cancer care to the point where the popular Cox proportional-hazards model provides misleading estimates of the treatment effect, according to a new study published April 15 in JAMA Oncology.

Cancer specialists at Vanderbilt University Medical Center, in partnership with biochemists and structural biologists across the Vanderbilt University campus, are taking “personalized” cancer therapy to a new level.

Tumors consume glucose at high rates, but a team of Vanderbilt researchers has discovered that cancer cells themselves are not the culprit, upending models of cancer metabolism that have been developed and refined over the last 100 years.

Pierre Massion, MD, Cornelius Vanderbilt Chair and Professor of Medicine, an internationally known expert on early detection and prevention strategies for lung cancer, died April 4 of an apparent heart attack. He was 58.

Triple-negative breast cancer cells engage in a “glutamine steal” — outcompeting T cells for the nutrient glutamine and impairing their ability to kill tumor cells, Vanderbilt researchers have discovered.